CE Mark For Biosensors BioFreedom™ Stent

In short

Biosensors International tells us it has gained CE Mark approval for its polymer-free drug-coated stent (DCS), BioFreedom™.


Biosensors says BioFreedom represents the latest development in stent technology. It features a micro-structured abluminal surface which is designed to permit the controlled release of Biolimus A9™ (BA9™) without the use of a carrier polymer as employed by some of its competitors. Also of note is the drug coating itself, BA9, which is a highly lipophilic anti-restenotic drug developed by Biosensors specifically for use with stents.

CE Mark approval for BioFreedom was supported by strong data from the BioFreedom First in Man study. In this study BioFreedom was compared to Boston Scientific’s Taxus™ Liberté™ drug-eluting stent (DES). At 12 months, BioFreedom demonstrated equivalent efficacy, measured by in-stent late lumen loss, compared with Taxus Liberté, with what the company describes as a trend towards superiority.

Median in-stent late lumen loss in patients receiving BioFreedom was reduced to 0.17 mm (compared with 0.35 mm in the Taxus Liberté group). Three-year clinical results, presented at TCT in October 2012, showed similar rates of Major Adverse Cardiac Events (MACE) between BioFreedom and Taxus Liberté, with no evidence of stent thrombosis in either group.

To further evaluate BioFreedom in a larger patient population, Biosensors recently announced initiation of enrolment in LEADERS FREE, the world’s first prospective, randomised double-blind trial between a DCS and bare-metal stent (BMS), exclusively involving patients at high risk of bleeding. The 2500 patient study has been designed to confirm that BioFreedom is as safe as a BMS in this patient group, and can deliver the anti-restenotic benefit of a DES, with only a one-month course of dual anti-platelet therapy administered to all patients. This trial will provide additional data to support the launch of BioFreedom in select markets during 2013.

The full commercial launch is currently anticipated during 2014.

Source: Biosensors International